- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 07.03. | AstraZeneca/Daiichi Sankyo's Enhertu not recommended by NICE for advanced breast cancer | ||
| 07.03. | Ipsen promotes Ioana Parsons to general manager for UK and Ireland | ||
| 07.03. | AI and over-digitalisation | ||
| 06.03. | Sandoz receives FDA approval for first denosumab biosimilars Wyost and Jubbonti | ||
| 06.03. | Merck KGaA and C4 Therapeutics enter protein degrader partnership worth $756m | ||
| 06.03. | Sanofi's Xenpozyme not recommended by NICE for ultra-rare disease ASMD | ||
| 06.03. | Novartis shares positive results for spinal muscular atrophy gene therapy Zolgensma | ||
| 06.03. | Drugmakers submit counteroffers to US Medicare pricing negotiations | ||
| 06.03. | Incentivising innovation in antibiotics | ||
| 05.03. | GSK's Jemperli combination recommended by NICE as first-line endometrial cancer treatment | ||
| 05.03. | Bayer and BridgeBio enter European partnership worth up to $310m for ATTR-CM | ||
| 05.03. | Sanofi's Rezurock fast-tracked by NHS for rare chronic graft versus host disease | ||
| 05.03. | Pfizer's RSV vaccine Abrysvo shown to maintain strong efficacy in older adults | ||
| 05.03. | First UK cancer patients receive Moderna's experimental mRNA therapy | ||
| 05.03. | Big truths, small spaces | ||
| 04.03. | Johnson & Johnson's Rybrevant granted FDA approval for lung cancer indications | ||
| 04.03. | AbbVie gains rights to OSE's chronic inflammation therapy in deal worth $713m | ||
| 04.03. | BMS shares positive long-term results for Zeposia in relapsing multiple sclerosis | ||
| 04.03. | New genetic risk tool could predict multiple sclerosis in young adults much earlier | ||
| 04.03. | Publicis Health UK promotes Katie McMorran and Clare Middleton as Langland group managing directors | ||
| 04.03. | Women in pharma | ||
| 01.03. | UKRI appoints iiCON to deliver £1.5m initiative to tackle infection transmission | ||
| 01.03. | FDA awards Orphan Drug Designation to SynaptixBio for rare brain disease therapy | ||
| 01.03. | Sanofi presents positive results for rilzabrutinib in chronic spontaneous urticaria | ||
| 01.03. | Shaping up for launch in '24: three areas to explore for pharma |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
